Abstract:Circulating single-molecule amplification and resequencing technology (cSMART) based on next-generation sequencing is highly sensitive, accurate and quantificational. The purpose of this study is to detect the status of 9 driver genes in Chinese NSCLC patients using cSMART and analyze the associations of gene status, clinical characteristics and prognosis. The tissue or plasma samples of 85 patients diagnosed NSCLC from Hangzhou First People's Hospital were collected. EGFR, KRAS, ALK, ROS1, PIK3CA, c-MET, RET, BRAF and HER2 genes were combined detection using cSMART. The association between gene status and clinical characteristics was analyzed by chi-square test and Fisher's exact. Kaplan-Meier survival curves were plotted for overall survival (OS) and analyzed with the log-rank test. Cox proportional hazards regression was used for multivariate analysis. Amongst 85 NSCLC patients, EGFR mutations were more frequent (57.6%), followed by KRAS mutation (18.8%), ALK mutation (10.6%), ALK fusion (9.4%), MET mutation (9.4%), PI3KCA mutation (8.2%), ROS1 fusion (3.5%), BRAF mutation (1.2%), RET fusion (1.2%) and HER2 mutation was not found. Furthermore, the abundances of gene mutation were relatively low. The EGFR mutation rate was higher in patients with adenocarcinoma histology than in those with squamous carcinoma histology (P=0.03). T790M mutation was more common in patients with a history of TKI treatment (P<0.01) and acquired T790M mutation was often accompanied by the original sensitive mutation (P<0.01). ALK fusion was more easily detected in tissue sample. All 8 MET gene exon14 skippings were found in adenocarcinoma histology and this gene alteration often happened after TKI treatment (P=0.02). OS was significantly improved in the EGFR mutation group compared with the wild group (median 32m vs 19m) (P=0.05). No significant survival difference between KRAS mutation and wild group was found (P>0.05). Among EGFR wild advanced NSCLC patients, the median OS of KRAS mutation group was 13 months while that of wild group was 26 months, but there was no significant difference (P>0.05). Multivariant analyzes showed gender, TKI treatment history and smoking history were independent prognostic factors in NSCLC (P<0.05). EGFR mutation is the most common driver gene in Chinese NSCLC, especially in adenocarcinoma patients, which often occurs in exon 19, 20 and 21 region. Then followed by KRAS mutation, it mostly occurs in exon 2. MET gene exon14 skipping is common in patients with adenocarcinoma or post-TKI treatment, which may be related to TKI resistance. Gender, smoking history and TKI treatment history could be independent prognostic factors in NSCLC.

EGFR Mutations, Gene Amplification, and Protein Expression and KRAS Mutations in Primary and Metastatic Tumors of Nonsmall Cell Lung Cancers and Their Clinical Implications: A Meta-Analysis

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Kras Mutations And Resistance To Egfr-Tkis Treatment In Patients With Non-Small Cell Lung Cancer: A Meta-Analysis Of 22 Studies

Comparison of ALK Status Between Primary and Corresponding Lymph Node Metastatic Tumors in Lung Cancer Patients

Association of mutation profiles with metastasis in patients with non-small cell lung cancer

Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non‐small‐cell lung cancer

Association Between PD-L1 Expression and Driver Gene Status in Non-Small-cell Lung Cancer: a Meta-Analysis

Prognostic Value of EGFR and KRAS in Resected Non-Small Cell Lung Cancer: a Systematic Review and Meta-Analysis.

Gene Status and Clinicopathologic Characteristics of Lung Adeno-Carcinomas with Mediastinal Lymph Node Metastasis

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review

Comparison of the C-Met Gene Amplification Between Primary Tumor and Metastatic Lymph Nodes in Non-Small Cell Lung Cancer.

Clinical impact of EGFR and KRAS mutations in surgically treated unifocal and multifocal lung adenocarcinoma

KRAS as a Prognostic and Predictive Marker in Metastatic Non-Small Cell Lung Carcinoma: A Systematic Review

Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments

[The Association Between EGFR Gene Amplification and the Prognosis in Non-small Cell Lung Cancer: A Meta-Analysis.].

Primary Concomitant EGFR T790M Mutation Predicted Worse Prognosis in Non-Small Cell Lung Cancer Patients.

Outcomes of EGFR, ALK, ROS1, BRAF, MET, and RET mutated non-small cell lung cancer with brain metastases (NSCLC BM).

P3.02-040 Driver Gene Detection in Chinese NSCLC Patients Using Csmart and Prognosis Analysis

Comprehensive Investigation of Oncogenic Driver Mutations in Chinese Non-Small Cell Lung Cancer Patients.

Epidermal Growth Factor Receptor Inhibitors As Adjuvant Treatment for Patients with Resected Non-Small Cell Lung Cancer Harboring EGFR Mutation: a Meta-Analysis of Randomized Controlled Clinical Trials